Trials / Completed
CompletedNCT05654181
A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, 4-PERIOD, CROSSOVER, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING ORAL DOSES OF PF-07328948 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study is the first clinical study with PF-07328948. The safety, tolerability, and plasma pharmacokinetics and pharmacodynamics of PF-07328948 after administration of escalating, single, oral doses will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-07328948 | investigational drug administered orally |
| DRUG | Placebo | Placebo matching active drug administered orally |
Timeline
- Start date
- 2022-10-17
- Primary completion
- 2023-05-03
- Completion
- 2023-05-03
- First posted
- 2022-12-16
- Last updated
- 2024-11-05
- Results posted
- 2024-11-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05654181. Inclusion in this directory is not an endorsement.